These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The unusual suspects--innate lymphoid cells as novel therapeutic targets in IBD. Goldberg R; Prescott N; Lord GM; MacDonald TT; Powell N Nat Rev Gastroenterol Hepatol; 2015 May; 12(5):271-83. PubMed ID: 25971811 [TBL] [Abstract][Full Text] [Related]
7. Evidence of IL-17 producing innate lymphoid cells in peripheral blood from patients with enteropathic spondyloarthritis. Triggianese P; Conigliaro P; Chimenti MS; Biancone L; Monteleone G; Perricone R; Monteleone I Clin Exp Rheumatol; 2016; 34(6):1085-1093. PubMed ID: 27782868 [TBL] [Abstract][Full Text] [Related]
8. The innate immune system and inflammatory bowel disease. Davies JM; Abreu MT Scand J Gastroenterol; 2015 Jan; 50(1):24-33. PubMed ID: 25523553 [TBL] [Abstract][Full Text] [Related]
9. Cells of the innate and adaptive immunity and their interactions in inflammatory bowel disease. Kmieć Z; Cyman M; Ślebioda TJ Adv Med Sci; 2017 Mar; 62(1):1-16. PubMed ID: 28126697 [TBL] [Abstract][Full Text] [Related]
10. ILC3 function as a double-edged sword in inflammatory bowel diseases. Zeng B; Shi S; Ashworth G; Dong C; Liu J; Xing F Cell Death Dis; 2019 Apr; 10(4):315. PubMed ID: 30962426 [TBL] [Abstract][Full Text] [Related]
11. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Tillack C; Ehmann LM; Friedrich M; Laubender RP; Papay P; Vogelsang H; Stallhofer J; Beigel F; Bedynek A; Wetzke M; Maier H; Koburger M; Wagner J; Glas J; Diegelmann J; Koglin S; Dombrowski Y; Schauber J; Wollenberg A; Brand S Gut; 2014 Apr; 63(4):567-77. PubMed ID: 23468464 [TBL] [Abstract][Full Text] [Related]
12. Innate lymphoid cell-derived cytokines in autoimmune diseases. Li S; Yang D; Peng T; Wu Y; Tian Z; Ni B J Autoimmun; 2017 Sep; 83():62-72. PubMed ID: 28479212 [TBL] [Abstract][Full Text] [Related]
15. The Role of Immune and Epithelial Stem Cells in Inflammatory Bowel Disease Therapy. Binienda A; Ziolkowska S; Hauge IH; Salaga M Curr Drug Targets; 2020; 21(14):1405-1416. PubMed ID: 32364073 [TBL] [Abstract][Full Text] [Related]
16. Group 3 ILCs: Peacekeepers or Troublemakers? What's Your Gut Telling You?! Pantazi E; Powell N Front Immunol; 2019; 10():676. PubMed ID: 31024537 [TBL] [Abstract][Full Text] [Related]
17. Dysregulation of Group 3 Innate Lymphoid Cells in the Pathogenesis of Inflammatory Bowel Disease. Forkel M; Mjösberg J Curr Allergy Asthma Rep; 2016 Oct; 16(10):73. PubMed ID: 27645534 [TBL] [Abstract][Full Text] [Related]
18. An immunomodulation strategy targeted towards immunocompetent cells or cytokines in inflammatory bowel diseases (IBD). Heresbach D; Sémana G; Gosselin M; Bretagne MG Eur Cytokine Netw; 1999 Mar; 10(1):7-15. PubMed ID: 10210767 [TBL] [Abstract][Full Text] [Related]
19. Regulation of intestinal health and disease by innate lymphoid cells. Sonnenberg GF Int Immunol; 2014 Sep; 26(9):501-7. PubMed ID: 24821261 [TBL] [Abstract][Full Text] [Related]
20. Anti-tumour necrosis factor-α antibodies and B cell homeostasis in human inflammatory bowel diseases. Defendenti C; Atzeni F; Malandrin S; Ardizzone S; Almasio PL; Saibeni S; Bezzio C; Bollani S; Salerno R; Declich P; Sarno Z; Bruno S; Talotta R; Sarzi-Puttini P Int Immunopharmacol; 2018 Jan; 54():329-335. PubMed ID: 29197269 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]